{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:31Z","timestamp":1791443011472,"version":"4.3.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clinthera.2013.09.023","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:49:31Z","timestamp":1383266971000},"page":"1890-1908","source":"Crossref","is-referenced-by-count":31,"title":["Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia"],"prefix":"10.1016","volume":"35","author":[{"given":"Malcolm","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakti","family":"Kothare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Yu","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.09.023_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials","volume":"62","author":"Davis","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/01.jcp.0000245563.06660.0f","article-title":"Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia","volume":"26","author":"Kinon","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2013.09.023_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4088\/JCP.v66n0704","article-title":"Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics","volume":"66","author":"Silva de Lima","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","article-title":"Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission","volume":"40","author":"Valenstein","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2013.09.023_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1185\/030079903125002270","article-title":"Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications","volume":"19","author":"Al-Zakwani","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.09.023_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-10-2","article-title":"The cost of relapse and the predictors of relapse in the treatment of schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3111\/13696990701646825","article-title":"Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia","volume":"10","author":"Beauclair","year":"2007","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2013.09.023_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","article-title":"e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)","volume":"24","author":"Olivares","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00004714-200108000-00006","article-title":"A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania","volume":"21","author":"Meehan","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2013.09.023_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib13","unstructured":"Eli Lilly and Company. Study F1D-EW-LOBE Clinical Study Summary: a study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of an intramuscular formulation of depot olanzapine (pamoate salt) in stable schizophrenic subjects. PhRMA Clinical Study Results Database. http:\/\/www.lillytrials.com\/results\/ZyprexaLAI.pdf. Accessed August 31, 2012."},{"key":"10.1016\/j.clinthera.2013.09.023_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","article-title":"An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia","volume":"69","author":"Lauriello","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Report"},{"key":"10.1016\/j.clinthera.2013.09.023_bib18","unstructured":"Guy W. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218\u2013222."},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2013.09.023_bib19","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.09.023_bib20","unstructured":"Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2010."},{"key":"10.1016\/j.clinthera.2013.09.023_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2013.09.023_bib22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0920-9964(02)00226-8","article-title":"Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand","volume":"61","author":"Gureje","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2013.09.023_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/PPA.S5734","article-title":"Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection","volume":"3","author":"Citrome","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2013.09.023_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-244X-10-45","article-title":"Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism","volume":"10","author":"McDonnell","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.023_bib26","unstructured":"Zyprexa RELPREVV [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2011."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T04:24:08Z","timestamp":1539231848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813009740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0149291813009740"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.09.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}